


7

L7 ANSWER 1 OF 9 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2003:384411 CAPLUS
DN 139:230713
TI A convenient synthesis of trisubstituted pyrido[2,3-d]pyrimidin-7-ones
AU Kaspavec, Jiri; Adams, Jerry L.; Sisko, Joseph; Silva, Domingos J.
CS Medicinal Chemistry Department, GlaxoSmithKline, Collegeville, PA,
19426, USA
SO Tetrahedron Letters (2003), 44(24), 4567-4570
CODEN: TELEAY; ISSN: 0040-4039
PB Elsevier Science Ltd.
DT Journal
LA English
AB A novel, highly efficient and scalable route for the synthesis of
trisubstituted pyrido[2,3-d]pyrimidin-7-ones was developed. The target
compds. were synthesized in five steps from readily available reagents
in about 40% overall yield.
IT **593277-87-3P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(synthesis of trisubstituted pyrido[2,3-d]pyrimidin-7-ones via
nucleophilic displacement followed by Suzuki coupling as the key
steps)
RN 593277-87-3 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 4,8-bis(2-chlorophenyl)-2-(1-methyl-4-
piperidinyl)- (9CI) (CA INDEX NAME)




RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT


searched 10/29/03

X

L7 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 2003:91257 CAPLUS
 DN 138:385389
 TI p38 Inhibitors: piperidine- and 4-aminopiperidine-substituted
 naphthyridinones, quinolinones, and dihydroquinazolinones
 AU Hunt, Julianne A.; Kallashi, Florida; Ruzek, Rowena D.; Sinclair, Peter
 J.; Ita, Ida; McCormick, Sherrie X.; Pivnichny, James V.; Hop, Cornelis
 E. C. A.; Kumar, Sanjeev; Wang, Zhen; O'Keefe, Stephen J.; O'Neill,
 Edward A.; Porter, Gene; Thompson, James E.; Woods, Andrea; Zaller,
 Dennis M.; Doherty, James B.
 CS Department of Medicinal Chemistry, Merck & Co., Inc., Rahway, NJ, 07065,
 USA
 SO Bioorganic & Medicinal Chemistry Letters (2003), 13(3), 467-470
 CODEN: BMCLE8; ISSN: 0960-894X
 PB Elsevier Science Ltd.
 DT Journal
 LA English
 OS CASREACT 138:385389
 GI



AB A series of C7-piperidine- and 4-aminopiperidine-substituted
 naphthyridinones, quinolinones, and dihydroquinazolinones were
 synthesized
 as highly potent inhibitors of both p38 mitogen-activated protein (MAP)
 kinase activity and tumor necrosis factor (TNF)-.alpha. release. The
 4-aminopentamethylpiperidine naphthyridinone I, which was designed to
 block metab. at major 'hot spots', combined excellent inhibitory potency
 with good oral bioavailability in the rat.
 IT **444660-65-5**
 RL: PAC (Pharmacological activity); BIOL (Biological study)
 (synthesis of piperidine and 4-aminopiperidine-substituted
 naphthyridinones, quinolinones, and dihydroquinazolinones as
 inhibitors
 of p38 MAP kinase and TNF-.alpha. release)
 RN 444660-65-5 CAPLUS
 CN 2(1H)-Quinazolinone, 5-(2-chloro-4-fluorophenyl)-1-(2,6-dichlorophenyl)-
 3,4-dihydro-7-[1-(1-methylethyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)



IT 444661-57-8P 444661-63-6P 444661-91-0P
 444661-92-1P 444665-12-7P 527680-12-2P
 527680-13-3P 527680-15-5P 527680-16-6P
 527680-17-7P 527680-18-8P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL
 (Biological study); PREP (Preparation)

(synthesis of piperidine and 4-aminopiperidine-substituted
 naphthyridinones, quinolinones, and dihydroquinazolinones as
 inhibitors

of p38 MAP kinase and TNF-.alpha. release)


RN 444661-57-8 CAPLUS

CN 1,6-Naphthyridin-2(1H)-one, 5-(2-chlorophenyl)-1-(2,6-dichlorophenyl)-7-
 [1-
 (1-methylethyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 444661-63-6 CAPLUS


CN 1,6-Naphthyridin-2(1H)-one, 5-(2-chlorophenyl)-1-(2,6-dichlorophenyl)-7-
 [[1-(1-methylethyl)-4-piperidinyl]amino]- (9CI) (CA INDEX NAME)




RN 444661-91-0 CAPLUS
 CN 2(1H)-Quinazolinone, 5-(2-chlorophenyl)-1-(2,6-dichlorophenyl)-3,4-dihydro-
 7-(4-piperidinylamino)- (9CI) (CA INDEX NAME)




RN 444661-92-1 CAPLUS
 CN 2(1H)-Quinazolinone, 5-(2-chlorophenyl)-1-(2,6-dichlorophenyl)-3,4-dihydro-
 7-[[1-(1-methylethyl)-4-piperidinyl]amino]- (9CI) (CA INDEX NAME)



RN 444665-12-7 CAPLUS
 CN 1,6-Naphthyridin-2(1H)-one, 5-(2-chlorophenyl)-1-(2,6-dichlorophenyl)-7-
 [(2,2,6,6-tetramethyl-4-piperidinyl)amino]- (9CI) (CA INDEX NAME)




RN 527680-12-2 CAPLUS
 CN 2(1H)-Quinolinone, 5-(2-chloro-4-fluorophenyl)-1-(2,6-dichlorophenyl)-7-
 [1-(1-methylethyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 527680-13-3 CAPLUS

CN 2(1H)-Quinolinone, 5-(2-chlorophenyl)-1-(2,6-dichlorophenyl)-7-[1-(1-methylethyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)



RN 527680-15-5 CAPLUS


CN 1,6-Naphthyridin-2(1H)-one, 5-(2-chlorophenyl)-1-(2,6-dichlorophenyl)-7-(4-piperidinylamino)- (9CI) (CA INDEX NAME)



RN 527680-16-6 CAPLUS

CN 1,6-Naphthyridin-2(1H)-one, 5-(2-chlorophenyl)-1-(2,6-dichlorophenyl)-7-[[3-(endo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]amino]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 527680-17-7 CAPLUS

CN 2(1H)-Quinazolinone, 5-(2-chlorophenyl)-1-(2,6-dichlorophenyl)-3,4-dihydro-

7-[[(3-endo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]amino]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 527680-18-8 CAPLUS

CN 2(1H)-Quinazolinone, 5-(2-chlorophenyl)-1-(2,6-dichlorophenyl)-3,4-dihydro-


7-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]- (9CI) (CA INDEX NAME)




IT 527680-19-9P

RL: PKT (Pharmacokinetics); SPN (Synthetic preparation); BIOL (Biological)

study); PREP (Preparation)
 (synthesis of piperidine and 4-aminopiperidine-substituted
 naphthyridinones, quinolinones, and dihydroquinazolinones as
 inhibitors
 of p38 MAP kinase and TNF-.alpha. release)
 RN 527680-19-9 CAPLUS
 CN 1,6-Naphthyridin-2(1H)-one, 5-(2-chlorophenyl)-1-(2,6-dichlorophenyl)-7-
 [(1,2,2,6,6-pentamethyl-4-piperidiny)amino]- (9CI) (CA INDEX NAME)



IT 444665-70-7P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation);
 RACT
 (Reactant or reagent)
 (synthesis of piperidine and 4-aminopiperidine-substituted
 naphthyridinones, quinolinones, and dihydroquinazolinones as
 inhibitors
 of p38 MAP kinase and TNF-.alpha. release)
 RN 444665-70-7 CAPLUS
 CN 2(1H)-Quinazolinone, 7-amino-5-(2-chlorophenyl)-1-(2,6-dichlorophenyl)-
 3,4-
 dihydro-3-[(4-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)



RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2003:70672 CAPLUS
DN 139:143286

TI A novel P450-catalyzed transformation of the 2,2,6,6-tetramethyl
piperidine moiety to a 2,2-dimethyl pyrrolidine in human liver
microsomes: characterization by high resolution quadrupole-time-of-
flight mass spectrometry and ¹H-NMR
AU Yin, Wenji; Doss, George A.; Stearns, Ralph A.; Chaudhary, Ashok G.;
Hop, Cornelis E.; Franklin, Ronald B.; Kumar, Sanjeev
CS Department of Drug Metabolism, Merck Research Laboratories, Rahway, NJ,
USA
SO Drug Metabolism and Disposition (2003), 31(2), 215-223
CODEN: DMDSAI; ISSN: 0090-9556
PB American Society for Pharmacology and Experimental Therapeutics
DT Journal
LA English
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *


AB We describe herein a novel metabolic fate of the 2,2,6,6-tetramethyl-
piperidine (2,2,6,6-TMPi) moiety to a ring-contracted 2,2-di-Me
pyrrolidine (2,2-DMPy) in human liver microsomal incubations. The
existence of this pathway was demonstrated for three compds. (I-III) of
varied structures suggesting that this may be a general
biotransformation
reaction for the 2,2,6,6-TMPi moiety. The 2,2-DMPy metabolites formed
in
incubations of the three compds. with human liver microsomes were
characterized by online high performance liq. chromatog. coupled to a
high
resoln. hybrid quadrupole-time-of-flight mass spectrometer. Suggested
elemental compn. obtained from accurate mass measurements of the mol.
ions
and fragment ions of the metabolites clearly indicated the loss of a
mass
equiv. to C₃H₆ from the parent 2,2,6,6-TMPi functionality. Addnl.
accurate tandem mass spectrometry data indicated that one of the
original
two gem-di-Me groups was intact in the metabolite structure. Proof of a
ring-contracted 2,2-DMPy structure was obtained using ¹H-NMR expts. on a
metabolite purified from liver microsomal incubations, which showed only
two geminal Me groups, instead of four in the parent compd.
Two-dimensional correlation spectroscopy and decoupling expts.
established
aliph. protons arranged in a pyrrolidine ring pattern. The fact that
the
formation of 2,2-DMPy metabolites in human liver microsomes was
NADPH-dependent suggested that this novel metabolic reaction was
catalyzed
by the cytochrome P 450 enzyme(s). Immunoinhibition studies in human
liver microsomal incubations using anti-P 450 monoclonal antibodies and
expts. with insect cell microsomes contg. individually expressed
recombinant human P 450 isoenzymes indicated that multiple P 450
isoenzymes were capable of catalyzing this novel metabolic
transformation.
IT 527680-19-9

RL: PKT (Pharmacokinetics); BIOL (Biological study)
(novel P 450-catalyzed transformation of the 2,2,6,6-tetra-Me
piperidine moiety to a 2,2-di-Me pyrrolidine in human liver

microsomes)

RN 527680-19-9 CAPLUS

CN 1,6-Naphthyridin-2(1H)-one, 5-(2-chlorophenyl)-1-(2,6-dichlorophenyl)-7-
[(1,2,2,6,6-pentamethyl-4-piperidinyl)amino]- (9CI) (CA INDEX NAME)




RE.CNT 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

X

L7 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2002:943599 CAPLUS
DN 138:271641
TI Design and synthesis of potent, orally bioavailable dihydroquinazolinone inhibitors of p38 MAP kinase
AU Stelmach, John E.; Liu, Luping; Patel, Sangita B.; Pivnichny, James V.; Scapin, Giovanna; Singh, Suresh; Hop, Cornelis E. C. A.; Wang, Zhen; Strauss, John R.; Cameron, Patricia M.; Nichols, Elizabeth A.; O'Keefe, Stephen J.; O'Neill, Edward A.; Schmatz, Dennis M.; Schwartz, Cheryl D.; Thompson, Chris M.; Zaller, Dennis M.; Doherty, James B.
CS Department of Medicinal Chemistry, Merck Research Laboratories, Rahway, NJ, 07065, USA
SO Bioorganic & Medicinal Chemistry Letters (2003), 13(2), 277-280
CODEN: BMCLE8; ISSN: 0960-894X
PB Elsevier Science Ltd.
DT Journal
LA English
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The development of potent, orally bioavailable (in rat) and selective dihydroquinazolinone inhibitors I (R = CO₂Me, R₁ = H, Br, 2-FC₆H₄, etc.;
R = OMe, R₁ = 2-Cl-4-FC₆H₃, 2,4-F₂C₆H₃, 2-ClC₆H₄), II (R₁ = 2-Cl-4-FC₆H₃, 2,4-F₂C₆H₃, 2-ClC₆H₄, X = none, O, NH, CH₂, CO, Y = CH, N) and III (R₂ = Me, Et, CHMe₂, etc.) of p38.alpha. MAP kinase is described. For example,
III (R₂ = CMe₃) was prepd. via the Still coupling of I (R = OSO₂CF₃, R₁ = 2-Cl-4-FC₆H₃) with 1-tert-butyl-4-(trimethylstannyl)-1,2,3,6-tetrahydropyridine. These analogs are hybrids of a pyridinylimidazole p38.alpha. inhibitor reported by Merck Research Labs. and VX-745. Optimization of the C-5 Ph and the C-7 piperidinyl substituents led to the identification of III (R₂ = CMe₃) which gave excellent suppression of TNF-.alpha. prodn. in LPS-stimulated whole blood (IC₅₀=10 nM) and good oral exposure in rats (F=68%, AUC_n PO=0.58 .mu.M h).
IT **444660-26-8**
RL: BSU (Biological study, unclassified); BIOL (Biological study) (prepn. of 1-(2,6-dichlorophenyl)quinazolinone derivs., their p38.alpha. MAP kinase inhibition, rat pharmacokinetics, and inhibition of TNF-.alpha. prodn. in monocytes, THP-1 cells and human whole blood)
RN 444660-26-8 CAPLUS
CN Piperazine, 1-[[5-(2-chloro-4-fluorophenyl)-1-(2,6-dichlorophenyl)-1,2,3,4-tetrahydro-2-oxo-7-quinazolinyl]carbonyl]- (9CI) (CA INDEX NAME)



IT 444660-60-0P

RL: BSU (Biological study, unclassified); PAC (Pharmacological activity);

PKT (Pharmacokinetics); RCT (Reactant); SPN (Synthetic preparation);

BIOL


(Biological study); PREP (Preparation); RACT (Reactant or reagent) (prepn. of 1-(2,6-dichlorophenyl)quinazolinone derivs., their p38.alpha. MAP kinase inhibition, rat pharmacokinetics, and inhibition

of

TNF-.alpha. prodn. in monocytes, THP-1 cells and human whole blood)

RN 444660-60-0 CAPLUS

CN 2(1H)-Quinazolinone, 5-(2-chloro-4-fluorophenyl)-1-(2,6-dichlorophenyl)-3,4-dihydro-7-(4-piperidinyl)- (9CI) (CA INDEX NAME)



IT 444660-17-7P 444660-40-6P 444660-58-6P

444660-59-7P 444660-62-2P 444660-63-3P

444660-64-4P 444660-65-5P 444660-66-6P

503184-90-5P 503184-92-7P 503184-93-8P

503184-94-9P 503184-95-0P 503184-96-1P

RL: BSU (Biological study, unclassified); PAC (Pharmacological activity);

PKT (Pharmacokinetics); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(prepn. of 1-(2,6-dichlorophenyl)quinazolinone derivs., their p38.alpha. MAP kinase inhibition, rat pharmacokinetics, and inhibition


of

TNF-.alpha. prodn. in monocytes, THP-1 cells and human whole blood)

RN 444660-17-7 CAPLUS

CN 2(1H)-Quinazolinone, 5-(2-chlorophenyl)-1-(2,6-dichlorophenyl)-3,4-dihydro-


7-(4-piperidinyloxy)-(9CI) (CA INDEX NAME)



RN 444660-40-6 CAPLUS


CN 2(1H)-Quinazolinone, 5-(2-chlorophenyl)-1-(2,6-dichlorophenyl)-3,4-dihydro-

7-(1-piperazinyl)-(9CI) (CA INDEX NAME)



RN 444660-58-6 CAPLUS


CN 2(1H)-Quinazolinone, 1-(2,6-dichlorophenyl)-5-(2,4-difluorophenyl)-3,4-dihydro-7-(4-piperidinyloxy)-(9CI) (CA INDEX NAME)



RN 444660-59-7 CAPLUS


CN 2(1H)-Quinazolinone, 5-(2-chlorophenyl)-1-(2,6-dichlorophenyl)-3,4-dihydro-

7-(4-piperidinyloxy)-(9CI) (CA INDEX NAME)




RN 444660-62-2 CAPLUS

CN 2(1H)-Quinazolinone, 5-(2-chloro-4-fluorophenyl)-1-(2,6-dichlorophenyl)-3,4-dihydro-7-(1-methyl-4-piperidinyl)- (9CI) (CA INDEX NAME)




RN 444660-63-3 CAPLUS

CN 2(1H)-Quinazolinone, 5-(2-chloro-4-fluorophenyl)-7-(1-cyclopropyl-4-piperidinyl)-1-(2,6-dichlorophenyl)-3,4-dihydro- (9CI) (CA INDEX NAME)




RN 444660-64-4 CAPLUS

CN 2(1H)-Quinazolinone, 5-(2-chloro-4-fluorophenyl)-1-(2,6-dichlorophenyl)-7-(1-ethyl-4-piperidinyl)-3,4-dihydro- (9CI) (CA INDEX NAME)




RN 444660-65-5 CAPLUS

CN 2(1H)-Quinazolinone, 5-(2-chloro-4-fluorophenyl)-1-(2,6-dichlorophenyl)-3,4-dihydro-7-[1-(1-methylethyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 444660-66-6 CAPLUS

CN 2(1H)-Quinazolinone, 5-(2-chloro-4-fluorophenyl)-7-[1-(cyclopropylmethyl)-4-piperidinyl]-1-(2,6-dichlorophenyl)-3,4-dihydro- (9CI) (CA INDEX NAME)




RN 503184-90-5 CAPLUS

CN 2(1H)-Quinazolinone, 5-(2-chloro-4-fluorophenyl)-1-(2,6-dichlorophenyl)-3,4-dihydro-7-(1-piperazinylmethyl)- (9CI) (CA INDEX NAME)




RN 503184-92-7 CAPLUS

CN Piperazine, 1-[[1-(2,6-dichlorophenyl)-5-(2,4-difluorophenyl)-1,2,3,4-tetrahydro-2-oxo-7-quinazolinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 503184-93-8 CAPLUS

CN 2(1H)-Quinazolinone, 5-(2-chloro-4-fluorophenyl)-7-[1-(2-cyclopropylethyl)-4-piperidinyl]-1-(2,6-dichlorophenyl)-3,4-dihydro- (9CI) (CA INDEX NAME)




RN 503184-94-9 CAPLUS

CN 2(1H)-Quinazolinone, 5-(2-chloro-4-fluorophenyl)-7-(1-cyclobutyl-4-piperidinyl)-1-(2,6-dichlorophenyl)-3,4-dihydro- (9CI) (CA INDEX NAME)




RN 503184-95-0 CAPLUS

CN 2(1H)-Quinazolinone, 5-(2-chloro-4-fluorophenyl)-7-[1-(cyclobutylmethyl)-4-piperidinyl]-1-(2,6-dichlorophenyl)-3,4-dihydro- (9CI) (CA INDEX NAME)



RN 503184-96-1 CAPLUS

CN 2(1H)-Quinazolinone, 5-(2-chloro-4-fluorophenyl)-1-(2,6-dichlorophenyl)-7-[1-(1,1-dimethylethyl)-4-piperidinyl]-3,4-dihydro- (9CI) (CA INDEX NAME)



IT 444660-41-7P 444660-45-1P 444661-91-0P

503184-88-1P 503184-89-2P 503184-91-6P

RL: BSU (Biological study, unclassified); SPN (Synthetic preparation);

BIOL (Biological study); PREP (Preparation)


(prepn. of 1-(2,6-dichlorophenyl)quinazolinone derivs., their p38.alpha. MAP kinase inhibition, rat pharmacokinetics, and inhibition

of

TNF-.alpha. prodn. in monocytes, THP-1 cells and human whole blood)


RN 444660-41-7 CAPLUS

CN 2(1H)-Quinazolinone, 1-(2,6-dichlorophenyl)-5-(2,4-difluorophenyl)-3,4-dihydro-7-(1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 444660-45-1 CAPLUS

CN 2(1H)-Quinazolinone, 1-(2,6-dichlorophenyl)-5-(2,4-difluorophenyl)-3,4-dihydro-7-(4-piperidinylamino)- (9CI) (CA INDEX NAME)



RN 444661-91-0 CAPLUS


CN 2(1H)-Quinazolinone, 5-(2-chlorophenyl)-1-(2,6-dichlorophenyl)-3,4-dihydro-7-(4-piperidinylamino)- (9CI) (CA INDEX NAME)



RN 503184-88-1 CAPLUS

CN 2(1H)-Quinazolinone, 5-(2-chloro-4-fluorophenyl)-1-(2,6-dichlorophenyl)-


3,4-dihydro-7-(4-piperidinyloxy)- (9CI) (CA INDEX NAME)



RN 503184-89-2 CAPLUS


CN 2(1H)-Quinazolinone, 5-(2-chlorophenyl)-1-(2,6-dichlorophenyl)-3,4-dihydro-

7-(1-piperazinylmethyl)- (9CI) (CA INDEX NAME)



RN 503184-91-6 CAPLUS


CN Piperazine, 1-[[5-(2-chlorophenyl)-1-(2,6-dichlorophenyl)-1,2,3,4-tetrahydro-2-oxo-7-quinazolinyl]carbonyl]- (9CI) (CA INDEX NAME)




RE.CNT 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 5 OF 9 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 2002:575047 CAPLUS
 DN 137:140533
 TI Preparation of 2,4,8-trisubstituted-8H-pyrido[2,3-d]pyrimidin-7-ones as
 CSBP/RK/p38 kinase inhibitors
 IN Adams, Jerry L.; Boehm, Jeffrey C.; Hall, Ralph; Jin, Qi; Kaspavec,
 Jiri; Silva, Domingos J.; Taggart, John J.
 PA Smithkline Beecham Corporation, USA
 SO PCT Int. Appl., 203 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002059083	A2	20020801	WO 2001-US50493	20011023
	WO 2002059083	A3	20030410		
	W:		AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM		
	RW:		GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG		
	EP 1333833	A2	20030813	EP 2001-994463	20011023
	R:		AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR		
	BR 2001014829	A	20030923	BR 2001-14829	20011023
	NO 2003001794	A	20030623	NO 2003-1794	20030422
PRAI	US 2000-242461P	P	20001023		
	US 2001-310349P	P	20010806		
	US 2001-326618P	P	20011002		
	WO 2001-US50493	W	20011023		
OS	MARPAT 137:140533				
GI					



I



II

AB Title compds. I [wherein X = R2, OR2, SOO-2R2, (CH2)nNR10SOO-2R2, (CH2)nNR10COR2, (CH2)nNR4R14, or (CH2)nN(R2)2; R1 = (un)substituted (hetero)aryl; R2 = H, (un)substituted alkyl, cycloalkyl(alkyl), (hetero)aryl(alkyl), heterocycl(alkyl), alkylamino, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, etc.; R3 = (un)substituted alkyl, cycloalkyl(alkyl), (hetero)aryl(alkyl), or heterocycl(alkyl); R4 and R14 = independently H or (un)substituted alkyl, cycloalkyl(alkyl), or aryl(alkyl); or NR4R14 = (un)substituted heterocycl(alkyl); R10 = H or alkyl; n = 0-10] were prepd. as CSBP/p38 kinase inhibitors. For example, sequential coupling of 4,6-dichloro-2-methylsulfanylpurimidine-5-carbaldehyde with aniline (76%) and phenylboronic acid (70%) gave 2-methylsulfanyl-4-phenyl-6-phenylaminopyrimidine-5-carbaldehyde.


Cyclization with bis(2,2,2-trifluoroethyl) (methoxycarbonylmethyl)phosphonate in the presence of 18-crown-6 and bis(trimethylsilyl)amide in THF afforded the 8H-pyrido[2,3-d]pyrimidin-7-one II (91%). The latter exhibited pos. inhibitory activity in the CSBP/p38 kinase binding assay with $IC_{50} < 10 \mu M$. I are useful for the treatment of a variety of CSBP/p38 kinase mediated diseases, such as arthritis, sepsis, stroke, asthma, pulmonary disease, osteoporosis, congestive heart failure, the common cold or respiratory viral infections, etc. (no data).

IT **444608-52-0P**, 8-(2,6-Difluorophenyl)-4-(4-fluoro-2-methylphenyl)-2-(2-oxo-2-thiomorpholin-4-ylethylamino)-8H-pyrido[2,3-d]pyrimidin-7-one
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(CSBP/p38 kinase inhibitor; prepn. of pyridopyrimidinones as CSBP/RK/p38 kinase inhibitors by cyclization reactions of (phenylamino)pyrimidinecarbaldehyde derivs.)

RN 444608-52-0 CAPLUS

CN Thiomorpholine, 4-[[[8-(2,6-difluorophenyl)-4-(4-fluoro-2-methylphenyl)-7,8-dihydro-7-oxopyrido[2,3-d]pyrimidin-2-yl]amino]acetyl]- (9CI) (CA INDEX NAME)



IT **444606-42-2P**, 4,8-Bis(2-chlorophenyl)-2-(piperidin-4-ylamino)-8H-pyrido[2,3-d]pyrimidin-7-one **444606-45-5P**, 4,8-Bis(2-chlorophenyl)-2-(1-methylpiperidin-4-ylamino)-8H-pyrido[2,3-d]pyrimidin-

7-

one **444606-67-1P**, 8-(2,6-Difluorophenyl)-4-(4-fluoro-2-methylphenyl)-2-[(1-methylpiperidin-4-yl)amino]-8H-pyrido[2,3-d]pyrimidin-7-one **444607-45-8P**, 2-Cyclohexylamino-4-(4-fluoro-2-methylphenyl)-8-(2-fluorophenyl)-8H-pyrido[2,3-d]pyrimidin-7-one **444607-46-9P**, 2-(Tetrahydropyran-4-ylamino)-4-(4-fluoro-2-methylphenyl)-8-(2-fluorophenyl)-8H-pyrido[2,3-d]pyrimidin-7-one **444607-48-1P**, 2-Cyclohexylamino-4-(4-fluoro-2-methylphenyl)-8-(2,6-difluorophenyl)-8H-pyrido[2,3-d]pyrimidin-7-one **444607-49-2P**, 2-(Tetrahydropyran-4-ylamino)-4-(4-fluoro-2-methylphenyl)-8-(2,6-difluorophenyl)-8H-pyrido[2,3-d]pyrimidin-7-one **444607-51-6P**, trans-2-(4-Hydroxycyclohexylamino)-4-(4-fluoro-2-methylphenyl)-8-(2-fluorophenyl)-8H-pyrido[2,3-d]pyrimidin-7-one **444607-54-9P**, trans-2-(4-Hydroxycyclohexylamino)-4-(4-fluoro-2-methylphenyl)-8-(2,6-difluorophenyl)-8H-pyrido[2,3-d]pyrimidin-7-one **444607-58-3P**, 1-[2-[[[8-(2,6-Difluorophenyl)-4-(4-fluoro-2-methylphenyl)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidin-2-yl]amino]ethyl]-3-phenylurea


444607-59-4P, 1-[2-[[8-(2,6-Difluorophenyl)-4-(4-fluoro-2-methylphenyl)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidin-2-yl]amino]ethyl]-3-cyclohexylurea **444607-60-7P**, 1-[2-[[8-(2,6-Difluorophenyl)-4-(4-fluoro-2-methylphenyl)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidin-2-yl]amino]ethyl]-3-(3-fluorophenyl)urea **444607-62-9P**
444607-67-4P 444607-74-3P 444607-95-8P
444607-97-0P, 4-(4-Fluoro-2-methylphenyl)-2-[(trans-4-hydroxycyclohexyl)amino]-8-o-tolyl-8H-pyrido[2,3-d]pyrimidin-7-one
444608-03-1P, 2-Cyclohexylamino-4-(4-fluoro-2-methylphenyl)-8-o-tolyl-8H-pyrido[2,3-d]pyrimidin-7-one **444608-05-3P**, 4-(4-Fluoro-2-methylphenyl)-2-(tetrahydropyran-4-ylamino)-8-o-tolyl-8H-pyrido[2,3-d]pyrimidin-7-one **444608-13-3P**, 8-(2,6-Difluorophenyl)-4-(4-fluoro-2-methylphenyl)-2-[(2-oxo-2-pyrrolidin-1-ylethyl)amino]-8H-pyrido[2,3-d]pyrimidin-7-one **444608-16-6P**, 4-(4-Fluoro-2-methylphenyl)-2-morpholin-4-yl-8-o-tolyl-8H-pyrido[2,3-d]pyrimidin-7-one **444608-18-8P**, 8-(2,6-Difluorophenyl)-4-(4-fluoro-2-methylphenyl)-2-[(1SR,2SR)-2-hydroxycyclohexyl]amino]-8H-pyrido[2,3-d]pyrimidin-7-one **444608-22-4P**, 8-(2,6-Difluorophenyl)-4-(4-fluoro-2-methylphenyl)-2-[[2-(1H-tetrazol-5-yl)ethyl]amino]-8H-pyrido[2,3-d]pyrimidin-7-one **444608-23-5P**, N-Cyclopropyl-2-[[8-(2,6-difluorophenyl)-4-(4-fluoro-2-methylphenyl)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidin-2-yl]amino]acetamide
444608-25-7P, 8-(2,6-Difluorophenyl)-4-(4-fluoro-2-methylphenyl)-2-[(1H-tetrazol-5-ylmethyl)amino]-8H-pyrido[2,3-d]pyrimidin-7-one
444608-28-0P, 8-(2,6-Difluorophenyl)-4-(4-fluoro-2-methylphenyl)-2-[(1SR,2SR)-2-hydroxycyclopentylamino]-8H-pyrido[2,3-d]pyrimidin-7-one
444608-31-5P, 8-(2,6-Difluorophenyl)-4-(4-fluoro-2-methylphenyl)-2-[[2-oxo-2-(3-oxopiperazin-1-yl)ethyl]amino]-8H-pyrido[2,3-d]pyrimidin-7-one
444608-32-6P, 8-(2,6-Difluorophenyl)-4-(4-fluoro-2-methylphenyl)-2-[[5-methyl-4H-[1,2,4]triazol-3-yl)methyl]amino]-8H-pyrido[2,3-d]pyrimidin-7-one **444608-33-7P**, 8-(2,6-Difluorophenyl)-4-(4-fluoro-2-methylphenyl)-2-[(1,1-dioxotetrahydro-1-thiophen-3-ylmethyl)amino]-8H-pyrido[2,3-d]pyrimidin-7-one
444608-35-9P, 8-(2,6-Difluorophenyl)-4-(4-fluoro-2-methylphenyl)-2-[(3-methylisoxazol-5-ylmethyl)amino]-8H-pyrido[2,3-d]pyrimidin-7-one
444608-37-1P, 8-(2,6-Difluorophenyl)-4-(4-fluoro-2-methylphenyl)-2-[[3S,4S]-4-hydroxy-1,1-dioxotetrahydrothiophen-3-yl]amino]-8H-pyrido[2,3-d]pyrimidin-7-one **444608-39-3P**, 8-(2,6-Difluorophenyl)-4-(4-fluoro-2-methylphenyl)-2-[(2-oxo-2,3-dihydropyrimidin-4-yl)amino]-8H-pyrido[2,3-d]pyrimidin-7-one **444608-40-6P**, 8-(2,6-Difluorophenyl)-4-(4-fluoro-2-methylphenyl)-2-[(1H-imidazol-2-ylmethyl)amino]-8H-pyrido[2,3-d]pyrimidin-7-one **444608-41-7P**, 8-(2,6-Difluorophenyl)-4-(4-fluoro-2-methylphenyl)-2-[(1H-[1,2,4]triazol-3-yl)amino]-8H-pyrido[2,3-d]pyrimidin-7-one **444608-42-8P**, 8-(2,6-Difluorophenyl)-4-(4-fluoro-2-methylphenyl)-2-(1H-tetrazol-5-ylamino)-8H-pyrido[2,3-d]pyrimidin-7-one **444608-44-0P**, 8-(2,6-Difluorophenyl)-4-(4-fluoro-2-methylphenyl)-2-(tetrahydrofuran-3-ylamino)-8H-pyrido[2,3-d]pyrimidin-7-one **444608-47-3P**, 8-(2,6-Difluorophenyl)-4-(4-fluoro-2-methylphenyl)-2-[[2-(1H-imidazol-4-yl)ethyl]amino]-8H-pyrido[2,3-d]pyrimidin-7-one **444608-49-5P**, Cyclopropanecarboxylic acid [8-(2,6-difluorophenyl)-4-(4-fluoro-2-methylphenyl)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-2-yl]amide **444608-51-9P**, Cyclopropanecarboxylic acid (1-

cyclopropylmethanoyl [8-(2,6-difluorophenyl)-4-(4-fluoro-2-methylphenyl)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidin-2-yl]amide **444608-53-1P**,
 8-(2,6-Difluorophenyl)-4-(4-fluoro-2-methylphenyl)-2-[(tetrahydrofuran-2-ylmethyl)amino]-8H-pyrido[2,3-d]pyrimidin-7-one **444608-54-2P**,
 8-(2,6-Difluorophenyl)-4-(4-fluoro-2-methylphenyl)-2-[[2-(3-hydroxyazetidin-1-yl)-2-oxoethyl]amino]-8H-pyrido[2,3-d]pyrimidin-7-one **444608-57-5P**, (1SR,2RS)-2-[[8-(2,6-Difluorophenyl)-4-(4-fluoro-2-methylphenyl)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidin-2-yl]amino]cyclopentanecarboxamide **444608-61-1P**,
 8-(2,6-Difluorophenyl)-2-[[2-(1,1-dioxothiomorpholin-4-yl)-2-oxoethyl]amino]-4-(4-fluoro-2-methylphenyl)-8H-pyrido[2,3-d]pyrimidin-7-one **444608-62-2P**, 8-(2,6-Difluorophenyl)-4-(4-fluoro-2-methylphenyl)-2-[3-(2-oxopyrrolidin-1-yl)propylamino]-8H-pyrido[2,3-d]pyrimidin-7-one **444608-65-5P**, 8-(2,6-Difluorophenyl)-4-(4-fluoro-2-methylphenyl)-2-[[2-(5-oxo-4,5-dihydro[1,2,4]oxadiazol-3-yl)ethyl]amino]-8H-pyrido[2,3-d]pyrimidin-7-one
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(CSBP/p38 kinase inhibitor; prepn. of pyridopyrimidinones as CSBP/RK/p38 kinase inhibitors by cyclization reactions of (phenylamino)pyrimidinecarbaldehyde derivs.)


RN 444606-42-2 CAPLUS

CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 4,8-bis(2-chlorophenyl)-2-(4-piperidinylamino)- (9CI) (CA INDEX NAME)




RN 444606-45-5 CAPLUS

CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 4,8-bis(2-chlorophenyl)-2-[(1-methyl-4-piperidinyl)amino]- (9CI) (CA INDEX NAME)




RN 444606-67-1 CAPLUS

CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 8-(2,6-difluorophenyl)-4-(4-fluoro-2-methylphenyl)-2-[(1-methyl-4-piperidyl)amino]- (9CI) (CA INDEX NAME)




RN 444607-45-8 CAPLUS

CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 2-(cyclohexylamino)-4-(4-fluoro-2-methylphenyl)-8-(2-fluorophenyl)- (9CI) (CA INDEX NAME)



RN 444607-46-9 CAPLUS


CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 4-(4-fluoro-2-methylphenyl)-8-(2-fluorophenyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]- (9CI) (CA INDEX NAME)



RN 444607-48-1 CAPLUS


CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 2-(cyclohexylamino)-8-(2,6-

difluorophenyl)-4-(4-fluoro-2-methylphenyl)- (9CI) (CA INDEX NAME)



RN 444607-49-2 CAPLUS


CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 8-(2,6-difluorophenyl)-4-(4-fluoro-2-methylphenyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]- (9CI) (CA INDEX NAME)



RN 444607-51-6 CAPLUS

CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 4-(4-fluoro-2-methylphenyl)-8-(2-fluorophenyl)-2-[(trans-4-hydroxycyclohexyl)amino]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 444607-54-9 CAPLUS


CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 8-(2,6-difluorophenyl)-4-(4-fluoro-2-methylphenyl)-2-[(trans-4-hydroxycyclohexyl)amino]- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 444607-58-3 CAPLUS

CN Urea, N-[2-[[8-(2,6-difluorophenyl)-4-(4-fluoro-2-methylphenyl)-7,8-dihydro-7-oxopyrido[2,3-d]pyrimidin-2-yl]amino]ethyl]-N'-phenyl- (9CI) (CA INDEX NAME)




RN 444607-59-4 CAPLUS

CN Urea, N-cyclohexyl-N'-[2-[[8-(2,6-difluorophenyl)-4-(4-fluoro-2-methylphenyl)-7,8-dihydro-7-oxopyrido[2,3-d]pyrimidin-2-yl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 444607-60-7 CAPLUS

CN Urea, N-[2-[[8-(2,6-difluorophenyl)-4-(4-fluoro-2-methylphenyl)-7,8-dihydro-7-oxopyrido[2,3-d]pyrimidin-2-yl]amino]ethyl]-N'-(3-fluorophenyl)-
(9CI) (CA INDEX NAME)




RN 444607-62-9 CAPLUS

CN Benzamide, N-[2-[[8-(2,6-difluorophenyl)-4-(4-fluoro-2-methylphenyl)-7,8-dihydro-7-oxopyrido[2,3-d]pyrimidin-2-yl]amino]ethyl]- (9CI) (CA INDEX NAME)



RN 444607-67-4 CAPLUS


CN 2,4(1H,3H)-Pyrimidinedione, 5-[[8-(2,6-difluorophenyl)-4-(4-fluoro-2-methylphenyl)-7,8-dihydro-7-oxopyrido[2,3-d]pyrimidin-2-yl]amino]- (9CI)
(CA INDEX NAME)



RN 444607-74-3 CAPLUS


CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 8-(2,6-difluorophenyl)-4-(4-fluoro-2-methylphenyl)-2-[[(2R)-2-hydroxy-2-phenylethyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 444607-95-8 CAPLUS

CN Morpholine, 4-[[[8-(2,6-difluorophenyl)-4-(4-fluoro-2-methylphenyl)-7,8-dihydro-7-oxopyrido[2,3-d]pyrimidin-2-yl]amino]acetyl]- (9CI) (CA INDEX NAME)




RN 444607-97-0 CAPLUS

CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 4-(4-fluoro-2-methylphenyl)-2-[(trans-

4-


hydroxycyclohexyl)amino]-8-(2-methylphenyl)- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 444608-03-1 CAPLUS

CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 2-(cyclohexylamino)-4-(4-fluoro-2-methylphenyl)-8-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 444608-05-3 CAPLUS

CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 4-(4-fluoro-2-methylphenyl)-8-(2-methylphenyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]- (9CI) (CA INDEX NAME)




RN 444608-13-3 CAPLUS

CN Pyrrolidine, 1-[[[8-(2,6-difluorophenyl)-4-(4-fluoro-2-methylphenyl)-
7,8-
dihydro-7-oxopyrido[2,3-d]pyrimidin-2-yl]amino]acetyl]- (9CI) (CA INDEX
NAME)



RN 444608-16-6 CAPLUS


CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 4-(4-fluoro-2-methylphenyl)-8-(2-
methylphenyl)-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)



RN 444608-18-8 CAPLUS


CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 8-(2,6-difluorophenyl)-4-(4-fluoro-2-
methylphenyl)-2-[[[(1R,2R)-2-hydroxycyclohexyl]amino]-, rel- (9CI) (CA
INDEX NAME)

Relative stereochemistry.




RN 444608-22-4 CAPLUS

CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 8-(2,6-difluorophenyl)-4-(4-fluoro-2-methylphenyl)-2-[[2-(1H-tetrazol-5-yl)ethyl]amino]- (9CI) (CA INDEX NAME)




RN 444608-23-5 CAPLUS

CN Acetamide, N-cyclopropyl-2-[[8-(2,6-difluorophenyl)-4-(4-fluoro-2-methylphenyl)-7,8-dihydro-7-oxopyrido[2,3-d]pyrimidin-2-yl]amino]- (9CI) (CA INDEX NAME)



RN 444608-25-7 CAPLUS


CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 8-(2,6-difluorophenyl)-4-(4-fluoro-2-methylphenyl)-2-[(1H-tetrazol-5-yl)methyl]amino]- (9CI) (CA INDEX NAME)



RN 444608-28-0 CAPLUS


CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 8-(2,6-difluorophenyl)-4-(4-fluoro-2-methylphenyl)-2-[[1,2,3-triazol-4-ylmethyl]amino]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 444608-31-5 CAPLUS

CN Piperazinone, 4-[[[8-(2,6-difluorophenyl)-4-(4-fluoro-2-methylphenyl)-7,8-dihydro-7-oxopyrido[2,3-d]pyrimidin-2-yl]amino]acetyl]- (9CI) (CA INDEX NAME)




RN 444608-32-6 CAPLUS


CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 8-(2,6-difluorophenyl)-4-(4-fluoro-2-methylphenyl)-2-[[(5-methyl-1H-1,2,4-triazol-3-yl)methyl]amino]- (9CI)
(CA INDEX NAME)



RN 444608-33-7 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 8-(2,6-difluorophenyl)-4-(4-fluoro-2-methylphenyl)-2-[[(tetrahydro-1,1-dioxido-3-thienyl)methyl]amino]- (9CI)
(CA INDEX NAME)




RN 444608-35-9 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 8-(2,6-difluorophenyl)-4-(4-fluoro-2-methylphenyl)-2-[[(3-methyl-5-isoxazolyl)methyl]amino]- (9CI) (CA INDEX NAME)



RN 444608-37-1 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 8-(2,6-difluorophenyl)-4-(4-fluoro-2-


methylphenyl)-2-[[(3S,4S)-tetrahydro-4-hydroxy-1,1-dioxido-3-thienyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 444608-39-3 CAPLUS.


CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 8-(2,6-difluorophenyl)-2-[(1,2-dihydro-2-oxo-4-pyrimidinyl)amino]-4-(4-fluoro-2-methylphenyl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE


RN 444608-40-6 CAPLUS

CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 8-(2,6-difluorophenyl)-4-(4-fluoro-2-methylphenyl)-2-[(1H-imidazol-2-ylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 444608-41-7 CAPLUS


CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 8-(2,6-difluorophenyl)-4-(4-fluoro-2-methylphenyl)-2-(1H-1,2,4-triazol-3-ylamino)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE

RN 444608-42-8 CAPLUS


CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 8-(2,6-difluorophenyl)-4-(4-fluoro-2-methylphenyl)-2-(1H-tetrazol-5-ylamino)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE


RN 444608-44-0 CAPLUS

CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 8-(2,6-difluorophenyl)-4-(4-fluoro-2-methylphenyl)-2-[(tetrahydro-3-furanyl)amino]- (9CI) (CA INDEX NAME)




RN 444608-47-3 CAPLUS

CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 8-(2,6-difluorophenyl)-4-(4-fluoro-2-methylphenyl)-2-[[2-(1H-imidazol-4-yl)ethyl]amino]- (9CI) (CA INDEX NAME)




RN 444608-49-5 CAPLUS

CN Cyclopropanecarboxamide, N-[8-(2,6-difluorophenyl)-4-(4-fluoro-2-methylphenyl)-7,8-dihydro-7-oxopyrido[2,3-d]pyrimidin-2-yl]- (9CI) (CA INDEX NAME)




RN 444608-51-9 CAPLUS

CN Cyclopropanecarboxamide, N-(cyclopropylcarbonyl)-N-[8-(2,6-difluorophenyl)-4-(4-fluoro-2-methylphenyl)-7,8-dihydro-7-oxopyrido[2,3-d]pyrimidin-2-yl]- (9CI) (CA INDEX NAME)




RN 444608-53-1 CAPLUS

CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 8-(2,6-difluorophenyl)-4-(4-fluoro-2-methylphenyl)-2-[[(tetrahydro-2-furanyl)methyl]amino]- (9CI) (CA INDEX NAME)



RN 444608-54-2 CAPLUS


CN 3-Azetidinol, 1-[[[8-(2,6-difluorophenyl)-4-(4-fluoro-2-methylphenyl)-7,8-dihydro-7-oxopyrido[2,3-d]pyrimidin-2-yl]amino]acetyl]- (9CI) (CA INDEX NAME)



RN 444608-57-5 CAPLUS


CN Cyclopentanecarboxamide, 2-[[[8-(2,6-difluorophenyl)-4-(4-fluoro-2-methylphenyl)-7,8-dihydro-7-oxopyrido[2,3-d]pyrimidin-2-yl]amino]-, (1R,2S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 444608-61-1 CAPLUS

CN Thiomorpholine, 4-[[[8-(2,6-difluorophenyl)-4-(4-fluoro-2-methylphenyl)-7,8-dihydro-7-oxopyrido[2,3-d]pyrimidin-2-yl]amino]acetyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 444608-62-2 CAPLUS

CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 8-(2,6-difluorophenyl)-4-(4-fluoro-2-methylphenyl)-2-[[3-(2-oxo-1-pyrrolidiny)propyl]amino]- (9CI) (CA INDEX NAME)




RN 444608-65-5 CAPLUS

CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 8-(2,6-difluorophenyl)-2-[[2-(2,5-dihydro-5-oxo-1,2,4-oxadiazol-3-yl)ethyl]amino]-4-(4-fluoro-2-methylphenyl)- (9CI) (CA INDEX NAME)



X


L7 ANSWER 7 OF 9 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2002:357940 CAPLUS
DN 137:78846
TI An Expedient Synthesis of Highly Functionalized Naphthyridones and
Quinolines from a Common N-Aryl Pyridinone Template
AU Savarin, Cecile G.; Murry, Jerry A.; Dormer, Peter G.
CS Department of Process Research, Merck Research Laboratories, Rahway, NJ,
07065, USA
SO Organic Letters (2002), 4(12), 2071-2074
CODEN: ORLEF7; ISSN: 1523-7060
PB American Chemical Society
DT Journal
LA English
OS CASREACT 137:78846
AB The authors describe a new base-mediated process for the formation of
N-arylpyridinones and their use for the prepn. of naphthyridones and
quinolines. The cyclization of various hindered enamines with Me
propiolate proceeds efficiently in the presence of NaOH to afford the
corresponding N-arylpyridinones. These substrates were then found to
undergo subsequent cyclizations to afford highly functionalized
naphthyridones and quinolines.
IT **439942-70-8P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of naphthyridones and quinolines from N-arylpyridinones)
RN 439942-70-8 CAPLUS
CN 6-Quinolinecarboxylic acid, 5-(2-chlorophenyl)-1-(2,6-dichlorophenyl)-
1,2-dihydro-2-oxo-7-phenyl-, methyl ester (9CI) (CA INDEX NAME)



RE.CNT 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 8 OF 9 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 2001:283958 CAPLUS
 DN 134:311201
 TI Preparation of isoxazoloquinolinones as inhibitors of multidrug
 resistance protein 1.
 IN Bonjouklian, Rosanne; Johnson, Douglas Webb; Lander, Peter Ambrose;
 Lohman, Mark Christopher; Patel, Vinod Francis; Vepachedu,
 Sreenivasarao; Xie, Yongping
 PA Eli Lilly and Company, USA
 SO PCT Int. Appl., 160 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001027116	A2	20010419	WO 2000-US21980	20000922
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	EP 1224189	A2	20020724	EP 2000-968314	20000922
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL			
PRAI	US 1999-158175P	P	19991007		
	US 1999-169784P	P	19991209		
	WO 2000-US21980	W	20000922		
OS	MARPAT 134:311201				
GI					



AB Title compds. [I; A = atoms to form a 5-membered (substituted) heteroaryl ring contg. N and a 2nd heteroatom selected from N, O, S; R = (CH₂)_mCHR₁NHR₂, OCH₂CH₂NHR₂, NHR₂, etc.; R₀ = H, OH, alkyl, phenylalkyl, cycloalkylalkyl; m = 0-2; R₁ = H, alkyl; R₂ = H, COR₆, SO₂R₇, etc.; R₆ = alkyl, substituted cycloalkyl, aryl, OMe₃, heterocyclyl,


heterocyclalkyl, etc.; R7 = alkyl, (substituted) Ph; R9-R11 = H, halo, CO2R1, (substituted) aryl, thienyl, alkoxy, alkylphenyl, alkenyl], were prepd. Thus, N-(3,4,5-trimethoxyphenyl)-3-[3-(2-chloro-5-fluorophenyl)-5-chloroisoxazol-4-yl]aminophenylacetamide (prepn. given) was stirred with K2CO3 at -10.degree. for 3 h to give 31.1% title compd. (II). I were said to demonstrate a significant effect in reversing MRPl multiple drug resistance. I drug formulations are given.

IT 334970-84-2P 334970-85-3P 334970-86-4P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (prepn. of isoxazoloquinolinones as inhibitors of multidrug resistance protein 1)


RN 334970-84-2 CAPLUS

CN Benzeneacetamide, 3-[3-methyl-9-(1-naphthalenyl)-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl]-N-(3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 334970-85-3 CAPLUS

CN Benzeneacetamide, 3-[9-(4-methoxyphenyl)-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl]-N-(3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 334970-86-4 CAPLUS


CN Benzeneacetamide, 3-[9-(4-chlorophenyl)-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl]-N-(3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)




L7 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1977:584455 CAPLUS
 DN 87:184455
 TI Heterocycles from 2-amino ketones. XXIII. Reaction of o-amino ketones with dicarboxylic acids
 AU Kempter, G.; Rehbaum, D.; Schirmer, J.
 CS Sek. Chem./Biol., Paedagog. Hochsch. "Karl Liebknecht", Potsdam, Ger. Dem. Rep.
 SO Journal fuer Praktische Chemie (Leipzig) (1977), 319(4), 589-600
 CODEN: JPCEAO; ISSN: 0021-8383
 DT Journal
 LA German
 GI



AB Condensed quinolines I (X = CH₂, S, O; R = H, Cl, Me; R₁ = Ph, 4-MeC₆H₄) were obtained by condensing aminobenzophenones 4,2-R(R₁CO)C₆H₃NH₂ with (HO₂CCH₂)₂X. Reaction of HO₂C(CH₂)_n1CO₂H (n = 3, 4, 7) or o-HO₂CC₆H₄CH₂CH₂CO₂H with 4,2-RBzC₆H₃NH₂ (R = H, Cl, Br, NO₂) gave II [R₂ = (CH₂)_nCO₂H, o-CH₂C₆H₄OC₂H]. III were similarly obtained with homophthalic acid. Reaction of acid chlorides ClCOX₁COCl [X₁ = (CH₂)_m, CH₂SCH₂, CH₂OCH₂; m = 3, 4, 8] with 4,2-ClBzC₆H₃NH₂ gave (4,2-ClBzC₆H₃NHCO)₂X₁ which cyclized to IV with NH₃.
 IT 64571-72-8P 64571-73-9P 64571-74-0P 64571-75-1P
 RL: SPN (Synthetic preparation); PREP (Preparation) (prepn. of)
 RN 64571-72-8 CAPLUS
 CN Benzo[b][1,8]naphthyridin-2(1H)-one, 1-(2-benzoylphenyl)-3,4-dihydro-5-phenyl- (9CI) (CA INDEX NAME)




RN 64571-73-9 CAPLUS
 CN Benzo[b][1,8]naphthyridin-2(1H)-one, 1-(2-benzoyl-4-chlorophenyl)-7-chloro-3,4-dihydro-5-phenyl- (9CI) (CA INDEX NAME)




RN 64571-74-0 CAPLUS

CN Benzo[b][1,8]naphthyridin-2(1H)-one, 1-(2-benzoyl-4-methylphenyl)-3,4-dihydro-7-methyl-5-phenyl- (9CI) (CA INDEX NAME)




RN 64571-75-1 CAPLUS

CN Benzo[b][1,8]naphthyridin-2(1H)-one, 3,4-dihydro-1-[2-(4-methylbenzoyl)phenyl]-5-(4-methylphenyl)- (9CI) (CA INDEX NAME)




=> d l1; d l3; d his; log y
L1 HAS NO ANSWERS
L1 STR



G1 C,O,N
G2 C,N

Structure attributes must be viewed using STN Express query preparation.
L3 HAS NO ANSWERS
L3 STR



G1 C,O,N
G2 C,N

Structure attributes must be viewed using STN Express query preparation.
(FILE 'HOME' ENTERED AT 16:20:53 ON 29 OCT 2003)

FILE 'REGISTRY' ENTERED AT 16:21:00 ON 29 OCT 2003

L1 STRUCTURE UPLOADED
L2 588 S L1 FUL
L3 STRUCTURE UPLOADED
L4 5 S L3 SAM SUB=L2
L5 80 S L3 FUL SUB=L2
L6 508 S L2 NOT L5

FILE 'CAPLUS' ENTERED AT 16:22:58 ON 29 OCT 2003

L7 9 S L6

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

42.49

226.55

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-5.86

-5.86

STN INTERNATIONAL LOGOFF AT 16:25:13 ON 29 OCT 2003